Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    7683573 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Positive EGFR Mutation
Intervention: Drug: BIBW 2992

Indicates status has not been verified in more than two years